The effects of heme, when added as the ferric chloride salt, hemin, on human erythroid cells grown in a two-phase liquid culture system were studied. When added together with erythropoietin, on initiation of the second phase of the culture. hemin greatly accelerated hemoglobin (Hb) accumulation in these cells. The effect was greater during their early stages of maturation, suggesting that heme availability is then a rate-limiting step for Hb synthesis. Hemin increased preferentially the production of fetal Hb (HbF) compared with adult Hb; this was associated with a selective twofold elevation in y-mRNA levels. Using succinylacetone, a potent inhibitor of heme synthesis, we showed that exogenously supplied hemin could be incorporated into the de novo formed Hb. Therefore, the mechanism of hemin action may EME, FERRIC protoporphyrin IX, is an integral part of the hemoglobin (Hb) molecule. It is synthesized from glycine by an enzyme system in the mitochondria.' Externally supplied hemin (the ferric chloride salt of heme) is taken up and has a profound effect on proliferation and differentiation of hemopoietic progenitors.' For example, addition of hemin enhances colony formation by normal erythroid progenitor^^.^ and induces a program of erythroid maturation in transformed cell lines of murine' and human origin.'.'' In the human cell lines K-562 and HEL, this program includes the production of embryonic and fetal, but not adult, H b . 9 The ability of hemin to induce fetal Hb (HbF) production is of considerable clinical importance. An increase in HbF in patients with @-hemoglobinopathies (sickle cell anemia and @-thalassemia) may ameliorate the clinical symptoms of the underlying disease." In sickle cell anemia, not only do HbF-containing cells have a lower concentration of sickle Hb (HbS), but HbF directly inhibits polymerization of HbS, thus accounting for the lower propensity of such cells to form intracellular polymer and undergo sickling." In pthalassemia, the elevated y-chains should partially compensate for the deficiency in @-chains relative to a-chains. Recently, several pharmacologic agents, including hydroxyurea, have been used to stimulate HbF synthesis in patients with these disea~es.'~-l~ Previous reports on the ability of hemin to enhance HbF production by erythroid precursors were inconclusive; cells from only some patients with sickle cell anemia responded." In the present study, we determined the effect of hemin on the proliferation and Hb production by cultured erythroid precursors derived from normal individuals and from patients with sickle cell anemia and &thalassemia. Erythroid progenitors derived from peripheral blood (PB) were grown in two-phase liquid c~l t u r e , '~ their globin RNA content was measured by reverse transcriptase-polymerase chain reaction (PCR)20 and their Hb content was analyzed by high-performance liquid chromatography (HPLC)."
The results indicated that the addition of hemin, together with erythropoietin (Epo), at the onset of the second phase of the culture increased the proportion of HbF in cells by about threefold. This increase was associated with accelera- be several fold, including effects on globin gene transcription and posttranslational events, eg, supplying the prosthetic group for Hb assembly. Hemin increased HbF of cells derived from patients with sickle cell anemia and /3-thaliassemia as well as that of cells from normal donors. Moreover, when added in combination with other HbF-augmenting agents such as the cytotoxic drug, hydroxyurea, a synergistic effect was obtained, with considerably less cytotoxiciv than with hydroxyurea alone. These results have clinical Ipotential in light of the ameliorating effect that increased HbF has in patients with genetic diseases of the &globin chain and raise the possibility of combined treatment with hemin and other drugs now being used to treat these diseases. tion of hemoglobinization of the cells at early stages of maturation, with a selective twofold increase in y-mRNA content. When added in combination with other HbF-augmenting agents, such as hydroxyurea, a synergistic effect was obtained (1Cfold increase in HbF) with considerably less cytotoxicity than after treatment with hydroxyurea alone. These results raise the possibility that a combined treatment with hemin and other drugs may benefit patients.
MATERIALS AND METHODS

Erythroid cell cultures.
Blood was obtained from normal volunteers and from patients with either sickle cell anemia or 8-thalassemia. In the case of transfused patients, blood samples were withdrawn before transfusion. Erythroid progenitors were grown according to the two-phase liquid culture p r~t o c o l . '~~~~ In short, PB mononucleated cells were isolated by centrifugation on Ficoll-Hypaque and seeded in a-minimal essential medium supplemented with 10% fetal calf serum (FCS; both from GIBCO, Grand Island, NY), 1 pg/mL cyclosporin A (Sandoz, Basel, Switzerland), and 10% 5637 bladder-carcinoma cell-conditioned medium. 23 The cultures were incubated at 37°C in an atmosphere of 5% CO, in air with extra humidity.
After 7-day incubation in this phase-I culture, the nonadherent cells were harvested, washed, and recultured in phase 11, which contained fresh medium composed of a-medium, 30% fetal calf serum, 1% deionized bovine serum albumin, 1 X IO" mol/L pmercaptoethanol, 1.5 mmol/L glutamine, 1 X IO-' m o m dexamethasone, and 1 U/mL human recombinant Epo (Ortho Pharmaceutical CO, Raritan, NJ).
Hb-containing cells were determined by using the benzidine-HCI pr~cedure.'~ Mean cellular Hb (MCH) was calculated by dividing the total Hb content of the lysate by the number of benzidine-positive cells. Cell morphology was assessed microscopically on cytocentrifuge-prepared slides (Shandon, Cheshire, UK) stained with alkaline benzidine and Giemsa.
Preparation of hemin solurion. A stock solution of 5 mmol/L hemin was prepared as follows: 32.5 mg bovine hemin (GIBCO) was dissolved in 0.5 mL of IN NaOH for about 30 minutes; then, 0.5 mL of 0.5 mol& Tris base was added, followed by 10 mL of bovine serum albumin (10% in m-medium; Sigma Chemical CO, St Louis, MO). The mixture was neutralized with 0.5 mL of I N HCI, filtered through a 0.45-pm filter, and stored at 4°C for not more than a week.
HPLC. Cells were washed 3 times with phosphate-buffered saline, and the pellet was lysed in double-distilled water. After spinning for 1 minute in a microcentrifuge, the supernatant was collected and stored at 4°C. Hb proteins in the hemolysates were separated by cation-exchange HPLC (Maxima 820; Waters Chromatography Division, Millipore CO, Milford, MA), using Synchropak CM300 (250-mm X 4.6-mm) column (Synchron Inc, Lafayette, IN) and Bis-Tris (30 mmol/L) b~ffer.~'.'~ Standard Hb solutions (Isolab Inc, Akron, OH) were used for reference. Chromatograms of supernatants of hemin-containing cultures indicated that, under the conditions used, free hemin was eluted from the column in the first 10 minutes and it was well separated from heme-proteins (ie, Hb) that started to elute only after 22 minutes (data not shown).
Globin mRNA analysis. Cells were homogenized in guanidinium thiocynate, RNA was extracted, and polyadenylated RNA was isolated on an oligo (dT) cellulose column using the QuickPrep mRNA purification kit (Pharmacia LKB Biotechnology, Uppsala, Sweden). cDNA was synthesized using 1 pg RNA, reverse transcriptase, and globin-specific primers as previously described.'" DNA amplification was performed by the PCR using specific synthetic oligonucleotide primers (Applied Biosystems 380B DNA synthesizer, Foster City, CA) for either the y-or P-globin genes on a Perkin-Elmer Cetus DNA Thermal Cycler (Foster City, CA) for 35 cycles, melting at 94°C for 1 minute, annealing at 55°C for 1.5 minutes, and extending at 72°C for 1.5 minutes, and then maintained at 4°C. For quantitation, specific DNA standards were prepared so that the 5' and 3' ends were compatible with a globin-specific primer pair used to amplify the cDNA sample but that produced a PCR product with a different size. Multiple reaction tubes were prepared for each cDNA sample, and serial dilutions of the globin specific standard DNA was added to each tube" with 0.5 pL of a-'*P dCTP. The cycle number (25 cycles) was chosen to ensure that the reaction was within the exponential phase as determined by preliminary experiments. PCR products were analyzed by agarose gel electrophoresis, and the amount of "P incorporated into each PCR product was determined by liquid scintillation counting (LKB Mallac 1209). The amount of standard necessary to provide PCR products of equal intensity for the standard and cDNA sample was used to determine the amount of cDNA present. The determination for control samples were within twofold of the actual amount over a range of several log units.
RESULTS
The effect of hemin on HbF production was determined by growing human erythroid precursors in phase 11 of the two-phase liquid culture in the presence of 1 U/mL Epo and different concentrations of hemin. Cells were harvested on day 13 and were lysed, and their Hb content was then analyzed by HPLC. The results (Fig l ) show the dose-response effect of hemin on total Hb and the proportion of HbF in the cultures. At 100 pmol/L, hemin caused a 30% increase in total Hb (Fig lA) , which was because of some increase in cell number (Fig lB) , but a more significant increase in the MCH (Fig 1C) . At higher hemin concentrations, total Hb decreased, mainly because of a decrease in cell number (Fig 1B) . The proportion of HbF showed a dose-dependent increase (Fig 1D) . Similar results were obtained in cultures of cells derived from 6 normal donors. In subsequent experiments, hemin was used at 100 pmol/L. At this concentration, hemin increased the percentage of HbF by about threefold and the total Hb by about 1.5-fold when the cells reached the stage of orthochromatic normoblasts (on day 13).
Figure 2 depicts the HPLC chromatograms of lysates of normal cells from 6-day cultures in the absence or presence of hemin. The results indicated that (1) cells did not accumulate substantial amounts of intracellular free hemin, ( 2 ) hemin-treated cultures had about fivefold more total Hb content, and (3) hemin-treated cells showed a threefold increase in the percentage of HbF, which was associated with a decrease in the percentage of HbA as compared with that for untreated cells.
Adding hemin (100 pmoVL) to cells derived from patients with @-thalassemia or sickle cell anemia, who usually have higher-than-normal HbF levels, caused a similar proportional increase in the percentage of HbF (mean, threefold; range, twofold to fivefold) in each of these individuals (Fig 3) . We then determined the optimal time of addition of hemin to the cultures. The results (Fig 4) indicated that adding hemin, together with Epo, at the onset of phase I1 of normal cell cultures produced a maximal effect. When added at later times, the effect diminished, and after day 7, when all erythroid cells were already engaged in Hb accumulation as evidenced by benzidine staining, there was no effect at all. Adding hemin to phase I of the culture was ineffective, unless it was also added to phase 11. These results indicate that, to enhance HbF production, hemin has to be present during early stages of erythroid maturation, when Hb production is initiated. Figure 5 shows the effects of hemin on the kinetics of erythroid cell proliferation and accumulation of Hb. The changes in cell number (Fig 5A) , percentage of Hb-containing (benzidine-reactive) cells (Fig 5B) , total Hb content per culture (Fig 5C) , and Hb content per cell (MCH; Fig  5D) were followed up in phase I1 cultures initiated either with or without hemin. The results indicated that hemin had some effect on the kinetics of cell proliferation (20% increase on day 6), but that it had a major effect on the kinetics of Hb accumulation. With respect to all these parameters, the hemin effect was most pronounced at early stages of maturation (days 2 to 6). Figure 6 shows the temporal changes in proportion of HbF (%HbF) when hemin was added on onset of phase 11. The results indicated that both hemin-treated and untreated cultures had high %HbF levels at their early stages. But in hemin-treated cultures, Hb production was initiated earlier (benzidine-positive cells were already detected on day 3, as compared with day 5 in the control cultures) and was associated with higher %HbF. Although %HbF decreased with time in both cultures, it remained considerably higher throughout the period in hemin-treated cultures. On day 13. when the cells reached the stage of orthochromatic normoblasts, hemin-treated cultures contained a threefold higher %HbF than control cultures. The effect of hemin, added on the first day of phase 11, on p-and y-globin mRNA contents was next determined.
The results showed 2.2-fold more cytoplasmic y-mRNA on day 6 and 1.8-fold more on day 12 in hemin-treated cultures as compared with that for control cultures. No significant difference was detected between the cultures on either dates in the level of the 0-mRNA (Fig 7) . We next determined the ability of exogenously supplied hemin to serve as heme in maturing erythroid precursors. In the experiment presented in cultures. When hemin was added together with succinylacetone, Hb content was 120% that of the control. Hemin by itself increased the Hb content by 50% over the control. These results confirmed that succinylacetone effectively inhibits heme biosynthesis and that exogenously supplied hemin could replace endogenously produced heme for Hb formation.
The effect of many HbF-augmenting agents such as Sazacytidine and hydroxyurea is associated with cytotoxicity. In our experience, a combination of two such agents usually does not produce HbF levels higher than those obtained by each agent alone, mainly because of added toxicity (data not shown). Because hemin at moderate concentrations (up to T r e a t m e n t 200 p,mol/L) is not cytotoxic in this system and in some experiments even enhances erythroid cell proliferation and maturation, we tested the effect of a combination of hydroxyurea and hemin on the cultured cells. Hemin ( 1 0 pmol/ L) was added on the first day of phase 11, and different concentrations of hydroxyurea (25 to 2 0 pmol/L) were added on day S, and cells were harvested on day 13. The results show very large potentiation (up to 14-fold) of HbF production by the combined treatment, compared with treatment with each agent alone (Fig 9A) . This effect was obtained at much lower cytotoxicity, as evidenced by the higher cell yield, with the combination of hemin and hydroxyurea as compared with treatment with hydroxyurea alone (Fig  9B) .
DISCUSSION
Erythroid maturation requires the coordinate expression of multiple genes. For example, the hallmark of erythroid maturation, Hb production, involves the synthesis of several types of globin polypeptide chains and of heme, an ironcontaining protoporphyrin that serves as the prosthetic group of the Hb molecule. Heme is synthesized from glycine by mitochondrial enzymes, and its production depends on the activities of these enzymes and on a sufficient supply of iron. The heme synthetic enzymes are upregulated at the transcriptional level on initiation of erythroid differentia-
iron content, which is usually supplied by transferrin, depends on the number and affinity of transferrin receptors. Although these receptors are relatively few in number on other cell types, including erythroid cells before the stage of Hb synthesis, their number increases dramatically after the initiation of erythroid mat~ration.'~ One mechanism of regulation and coordination seems to be through the GATA-l binding motifs that many of these genes
The results of the present study indicate that exogenously supplied hemin (heme-ferric chloride) accelerated Hb accumulation at early stages of maturation, thereby suggesting that heme availability is a rate-limiting step in this process at these stages. This condition may be caused by either deficient cellular iron uptake because of lack of transferrin receptors or insufficient activity of one or more of the heme-pathway enzymes, with ferrochelatase being considered the limiting enzyme in erythroid cell^.'^,^' This suggestion is in agreement with numerous reports regarding the regulatory role hemin plays in erythroid cell mat~ration.'"'~ Using succinylacetone, a potent competitive inhibitor of 6-aminolevulonic acid dehydrogenase, the second enzyme in heme-synthetic p a t h~a y ,~' we showed in the present study that exogenously supplied hemin can replace endogenously synthesized heme and be incorporated into de novo produced Hb. Moreover, using "Fe and Mossbauer spectroscopy, we have previously shown in the human erythroleukemic K-562 cell line that, when iron is presented either as hemin or bound to transferrin, the former serves as a preferential source for Hb synthesis.'6 Similar results were recently obtained with normal erythroid precursors (manuscript in preparation).
Despite the high concentrations of extracellular hemin in our experiments, the cells did not accumulate a large excess (Fig 2) . We and others have found that hemin uptake by cultured erythroid cells downmodulates their surface receptors for t r a n~f e r r i n~~.~~.~' and for acid isoferritin," thus suggesting that the uptake of hemin is physiologically regulated. Whether hemin uptake is receptor-mediated is still unknown, although hemin receptors on liver cells have been reported!' Uptake of hemin during the early stages of maturation may accelerate Hb formation by affecting the rate of transcription of the globin genes, the processing and stability of their mRNA, or the efficiency of translation into globin
In the present study, we were able to show a selective increase in y-globin mRNA content (Fig 7) . Preliminary data suggest that it involves, at least in part, more efficient processing of the primary tran~cripts.4~ Hemin may also have a posttranslational effect, ie, by providing heme for completion and stabilization of the Hb molecules.
The present results also indicate that exogenously supplied hemin does not increase the production of all types of Hbs proportionally, but rather preferentially increases the production of HbF. A differential effect on transcription of some globin genes was also found in murine erythroleukemia cells."' Our results suggest that the preferential increase in HbF is related to hemin's ability to accelerate early Hb synthesis. Hemin is effective in enhancing HbF mainly if added at early stages of maturation (Fig 5) . In agreement with previous report^,^^-^' we showed that HbF is produced mainly during early stages of erythroid maturation and Hb accumuchains.",41-44 lation (Fig 6) . Accelerating Hb synthesis at these stages results in a higher proportion of HbF (Fig 6) . Even if the high HbF level drops off as the cells mature, as compared with untreated cells, hemin-treated cells maintain a higher content of HbF throughout the culture.
Our results indicated that hemin could enhance HbF production not only by normal cells but also by cells derived from patients with @-hemoglobinopathies. This finding has considerable clinical importance in light of the ameliorating effect that increased HbF has in such patients. The pharmacologic enhancement of HbF using a single agent has usually not produced the desired increase in HbF level to provide full clinical benefit. In addition, a wide variation in response was noticed among patients. Because the effect of many HbF-augmenting agents, such as 5-azacytidine and hydroxyurea, is usually associated with cytotoxicity, a combination therapy with such agents is unlikely. Indeed, treatment of cells in vitro by a combination of two such agents did not produce HbF levels higher than those obtained by each agent alone, mainly because of added toxicity (manuscript in preparation). Because hemin is not toxic at moderate doses and in many experiments enhances hemopoietic cell proliferation, we tested the effect of a combination of hydroxyurea and hemin on cultured cells. The results (Fig 7) show a large potentiation of HbF production by the combined treatment as compared with that of each agent alone. This effect was obtained with lower toxicity, as evidenced by the much higher cell yield when the combination was used. Protective effects of hemin were also observed in vitro with other cytotoxic drugs, eg, anthracyclins," and in vivo, in conjunction with Epo, in mice treated with azidothymidine."
Our results suggest that hemin, either alone or in combination with other drugs, might provide a potentially useful treatment for patients with @-hemoglobinopathies. Hemin has been proven to be well tolerated when used therapeutically in patients with acute intermittent porphyria." New derivatives with a longer shelf life and in vivo half-life (eg, heme arginate) have recently been prepared." These derivatives have been used for treatment of patients with myelodysplastic ~y n d r o m e .~~. '~ A major concern in using hemin in polytransfused patients is the risk of aggravating their iron overload. However, recently it has been found that increased erythropoiesis in such patients (when treated with Epo) requires iron s~pplementation."~~~ As an efficient donor of iron (or heme), hemin may serve this function. Therefore, the beneficial effect of hemin in these patients might be fourfold: For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From
